Reported about 13 hours ago
In a recent analysis, Jim Cramer acknowledged Novo Nordisk A/S (NYSE:NVO) as a solid growth stock but expressed a stronger preference for Eli Lilly, citing their promising drug pipeline, particularly for Alzheimer’s. Despite its potential, Novo Nordisk has seen a significant decline of 49.32% since then, leading investors to question its growth prospects compared to other stocks Cramer discusses.
Source: YAHOO